[Effectiveness of bemitil in recurrent erysipelas].

Abstract

The trial entered 66 patients with recurrent erysipelas treated conventionally with addition of either immunostimulator bemitil (0.25-0.5 g/day orally for 5-7 days) or placebo. The bemitil group was free of intoxication symptoms and local manifestations, discharged from hospital sooner than the controls. Therapeutic efficacy of bemitil is due to its promotion of mononuclear phagocytes function which acts as an essential mechanism of antibacterial defence activation in patients with recurrent erysipelas.

• Authors: L I Ratnikova
• Journal: Klinicheskaia meditsina (Klin Med (Mosk)) Vol. 69 Issue 7 Pg. 89-90 (Jul 1991) ISSN: 0023-2149 [Print] Russia (Federation)
• Vernacular Title: Effektivnost' bemitila pri retsidiviruiushcheĭ rozhe.
• PMID: 1942990 (Publication Type: Clinical Trial, Controlled Clinical Trial, English Abstract, Journal Article)

Chemical References

• Adjuvants, Immunologic
• Benzimidazoles
• Placebos
• bemethyl

Topics

• Adjuvants, Immunologic (administration & dosage)
• Adult
• Benzimidazoles (administration & dosage)
• Combined Modality Therapy
• Drug Administration Schedule
• Erysipelas (etiology, immunology, therapy)
• Humans
• Immune Tolerance (drug effects, immunology, radiation effects)
• Middle Aged
• Placebos
• Recurrence
• Ultraviolet Therapy